- Home
- BTAI vs IMRN Comparison
BTAI vs IMRN Comparison
Compare BTAI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- IMRN
- Stock Information
- Founded
- BTAI 2017
- IMRN 1994
- Country
- BTAI United States
- IMRN Australia
- Employees
- BTAI N/A
- IMRN N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- IMRN Health Care
- Exchange
- BTAI Nasdaq
- IMRN Nasdaq
- Market Cap
- BTAI 18.1M
- IMRN 15.0M
- IPO Year
- BTAI 2018
- IMRN N/A
- Fundamental
- Price
- BTAI $0.34
- IMRN $2.15
- Analyst Decision
- BTAI Buy
- IMRN Strong Buy
- Analyst Count
- BTAI 4
- IMRN 1
- Target Price
- BTAI $2.81
- IMRN $5.00
- AVG Volume (30 Days)
- BTAI 1.3M
- IMRN 21.6K
- Earning Date
- BTAI 03-11-2025
- IMRN 02-26-2025
- Dividend Yield
- BTAI N/A
- IMRN N/A
- EPS Growth
- BTAI N/A
- IMRN N/A
- EPS
- BTAI N/A
- IMRN N/A
- Revenue
- BTAI $2,276,000.00
- IMRN $3,271,194.00
- Revenue This Year
- BTAI $131.23
- IMRN N/A
- Revenue Next Year
- BTAI $45.79
- IMRN N/A
- P/E Ratio
- BTAI N/A
- IMRN N/A
- Revenue Growth
- BTAI 83.25
- IMRN 171.67
- 52 Week Low
- BTAI $0.30
- IMRN $1.59
- 52 Week High
- BTAI $4.17
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- BTAI 42.14
- IMRN 56.18
- Support Level
- BTAI $0.33
- IMRN $1.85
- Resistance Level
- BTAI $0.39
- IMRN $2.20
- Average True Range (ATR)
- BTAI 0.06
- IMRN 0.22
- MACD
- BTAI -0.00
- IMRN 0.01
- Stochastic Oscillator
- BTAI 9.27
- IMRN 57.47
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.